Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Sodium Valproate + 5-azacitidine + ATRA + Theophylline in Acute Myeloid Leukemia and High-risk Myelodysplasia
2005-000550-75Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valproic acid, azacitidine, tretinoin and theophylline in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Birmingham. Primary endpoints: Safety and tolerability of combination therapy and Anti-leukemic activity of combination therapy. Started Jan 2006; status: completed.
02
Drugs
valproic acidazacitidinetretinointheophylline
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-000550-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000550-75.